Loading filters...
50 results(scroll for more)
Generaladvanced2026
Real-World Comparison of Triplet Versus Doublet Therapy in Japanese Patients With High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Propensity-Weighted Analysis From the YUSHIMA Registry and Exploratory Bayesian Evidence Synthesis.
Yasuda Y et al. Prostate. 2026
Generaladvanced2026
Adapting the Bellmunt Risk Score for Prognostic Stratification in Metastatic Castration-Sensitive Prostate Cancer.
Yazgan SC et al. Prostate. 2026
Hormone-sensitiveadvanced2026
WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide.
Talmor B et al. Eur Urol Oncol. 2026
BRCA/HRRadvanced2026
Functional footprints of homologous recombination deficiency in prostate cancer revealed by ctDNA fragmentation and transcription factor accessibility.
Vlachos G et al. Br J Cancer. 2026
Hormone-sensitiveadvanced2026
Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study.
Shore ND et al. Prostate Cancer Prostatic Dis. 2026
Generaladvanced2026
Corticosteroid Use and Risk of Adverse Events in Metastatic Hormone-Sensitive Prostate Cancer.
Swami U et al. Prostate. 2026
Generaladvanced2026
Prognostic Impact of Initial Prostate Specific Antigen Half-Life After Abiraterone Acetate in High-Volume Metastatic Hormone-Sensitive Prostate Cancer: Who May Need Triplet Therapy?
Suzuki K et al. Prostate. 2026
BRCA/HRRAll Stages2026
Establishment and Characterization of Patient-Derived Xenograft Organoids for Personalized Treatment of Castration-Resistant Prostate Cancer.
Sunada T et al. Prostate. 2026
GeneralAll Stages2026
On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials.
Kayani M et al. Lancet Oncol. 2026
Generaladvanced2026
SPOP Mutations in Veterans With Prostate Cancer and Outcomes With Doublet and Triplet Therapy in De Novo Metastatic Hormone Sensitive Prostate Cancer.
Park JJ et al. Prostate. 2026
Hormone-sensitiveadvanced2026
Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancer.
Soon YY et al. BJU Int. 2026
Generaladvanced2026
Survival trend in metastatic prostate cancer two decades of real-world data on overall survival from Germany.
Sondermann M et al. Prostate Cancer Prostatic Dis. 2026
Bone metastasesadvanced2026
Genetics-Driven, Intensity-Modulated Adaptive Management of Patients With Metastatic Prostate Cancer.
Rosales RDR et al. Prostate. 2026
Generaladvanced2026
Post Hoc Subgroup Analysis of Clinical Outcomes in Patients With High-Risk Metastatic Hormone-Naïve Prostate Cancer: Results From a 3-Year Interim Analysis of the J-ROCK Study.
Mizokami A et al. Prostate. 2026
Generaladvanced2026
Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis.
Riaz IB et al. Eur Urol. 2026
Hormone-sensitiveadvanced2026
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study.
Fizazi K et al. Ann Oncol. 2026
Generaladvanced2026
Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.
Yanagisawa T et al. Prostate Cancer Prostatic Dis. 2026
PSMA+advanced2026
Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer.
Al-Khanaty A et al. BJU Int. 2026
PSMA+advanced2026
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study.
Sandhu S et al. Lancet Oncol. 2026
PSMA+advanced2026
[177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study.
Privé BM et al. Lancet Oncol. 2026
PSMA+advanced2026
Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancer.
Munzur AD et al. Clin Cancer Res. 2026
Generaladvanced2026
Beyond PSMA: theranostic cell surface targets in metastatic prostate cancer.
Ashraf B et al. Prostate Cancer Prostatic Dis. 2026
Generaladvanced2026
The Clinical Significance of Gallium-68 PSMA-11 PET-Derived SUVmax in the Management of Metastatic Hormone-Sensitive Prostate Cancer.
Kıkılı Cİ et al. Prostate. 2026
Hormone-sensitiveadvanced2026
The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With First-Line ARPI Therapy.
Tsutsumi T et al. Prostate. 2026
Generaladvanced2026
Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study.
Jayaram A et al. Nat Cancer. 2026
Hormone-sensitiveadvanced2026
Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial).
Gupta S et al. Prostate Cancer Prostatic Dis. 2026
BRCA/HRRadvanced2026
Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study.
Armstrong AJ et al. Eur Urol Oncol. 2026
Generaladvanced2026
Prognosis and Treatment Response in Aggressive-variant Prostate Cancer and Treatment-related Neuroendocrine Prostate Cancer: A Systematic Review and Meta-analysis.
Pedrani M et al. Eur Urol Oncol. 2026
BRCA/HRRadvanced2026
Positron Emission Tomography/Computed Tomography Imaging with [18F]PARPi for Precision Guidance of Poly ADP-ribose Polymerase Inhibitor Therapy in Homologous Recombination Repair Mutated and Nonmutated Metastatic Castration-resistant Prostate Cancer.
Ofner H et al. Eur Urol Oncol. 2026
Hormone-sensitiveadvanced2026
PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: Rationale, Mechanisms, and Clinical Applications.
Oudard S et al. Eur Urol Oncol. 2026
BRCA/HRRadvanced2026
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer.
Agarwal N et al. N Engl J Med. 2026
Hormone-sensitiveadvanced2026
The Impact of Early Modification of Upfront Androgen Receptor Signaling Inhibitors on Survival Outcomes in Metastatic Hormone-Sensitive Prostate Cancer.
Narita S et al. Prostate. 2026
Generaladvanced2026
First-Line Systemic Treatments for Metastatic Hormone-Sensitive Prostate Cancer: Updated Systematic Review and Network Meta-analysis.
Miyajima K et al. J Urol. 2026
Hormone-sensitiveearly2026
Long-Term Follow-Up of Neoadjuvant Enzalutamide Plus Androgen Deprivation Therapy in Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Feasibility Trial.
Millan B et al. Prostate. 2026
Generaladvanced2026
A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer.
Medina S et al. Clin Cancer Res. 2026
Hormone-sensitiveAll Stages2026
MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer.
Gulla S et al. Cancer Res. 2026
GeneralAll Stages2026
Apalutamide + Abiraterone Acetate plus Prednisone + Leuprolide with Stereotactic, Ultra-Hypofractionated Radiation in Very High-Risk Prostate Cancer: A Single-Arm, Phase 2 Study.
McBride SM et al. Clin Cancer Res. 2026
Generaladvanced2026
Pembrolizumab Plus Lenvatinib in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort E.
Augustin M et al. Eur Urol Oncol. 2026
Hormone-sensitiveadvanced2026
Prognostic Effect of KELIM Score of Prostate-Specific Antigen in Hormone-Sensitive Prostate Cancer Patients Treated With Novel Androgen Receptor Inhibitors: Pioneering New Ways.
Ilhan Y et al. Prostate. 2026
GeneralAll Stages2026
Efficacy of Early Switching From Docetaxel to Cabazitaxel in Castration-Resistant Prostate Cancer.
Kawai T et al. Prostate. 2026
Generaladvanced2026
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).
McKay RR et al. J Clin Oncol. 2026
Bone metastasesadvanced2026
Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial.
Dalla Volta A et al. Prostate Cancer Prostatic Dis. 2026
GeneralAll Stages2026
Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis.
Hatayama T et al. Prostate. 2026
Hormone-sensitiveAll Stages2026
Loss of GPR133 Promotes Enzalutamide Resistance in Prostate Cancer by Upregulating HSD3B1 and Intratumoral Androgen Synthesis.
Wei L et al. Prostate. 2026
GeneralAll Stages2026
Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12.
Vicier C et al. Eur J Cancer. 2026
Bone metastasesadvanced2026
Bone Metastasis Distribution Matters: Prognostic Effect of the Axial-to-Peripheral Ratio in Metastatic Hormone-Sensitive Prostate Cancer.
Gürbüz AF et al. Prostate. 2026
Generaladvanced2026
Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancer.
Friedrich NA et al. Prostate Cancer Prostatic Dis. 2026
GeneralAll Stages2026
Inhibition of c-FLIP alongside TRAIL treatment suppresses prostate cancer stem cell activity.
Turnham DJ et al. Br J Cancer. 2026
GeneralAll Stages2026
Signaling Under Stress: Targeting the Glucocorticoid Receptor in Cancer.
Flint MS et al. Cancer Res. 2026
Generaladvanced2026
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.
Fizazi K et al. Lancet Oncol. 2026